SOURCE: The Bedford Report

The Bedford Report

April 13, 2011 08:16 ET

Speculative Drug Developers Take Aim at Blockbuster Status

The Bedford Report Provides Analyst Research on MannKind & Keryx Biopharmaceuticals

NEW YORK, NY--(Marketwire - Apr 13, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on MannKind Corporation (NASDAQ: MNKD) and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Access to the full company reports can be found at:

MannKind Corporation has been seeking FDA approval for an inhalable form of insulin called Afrezza. Shares of the company were sent plummeting earlier this year after the FDA asked for two new studies of the device in patients with Type 1 and Type 2 diabetes. Alfred Mann -- the company's founder -- was still optimistic and encouraged by the fact the FDA has not asked for anything other than these bridging studies, in terms of clinical work.

Keryx Biopharmaceuticals develops pharmaceuticals for the treatment of diseases such as diabetes, renal disease and cancer. The company's oral, iron-based drug "Zerenex" is in phase III testing under a Special Protocol Assessment agreement with the FDA as a treatment for elevated phosphate levels in patients with end-stage renal disease.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information